Sividon Diagnostics' Acquisition

Sividon Diagnostics was acquired by Myriad Genetics on May 31, 2016.

Sividon Diagnostics develops breast cancer prognostic tests. Sividon's core EndoPredict product is a kit-based RNA expression test designed to assess the aggressiveness of breast cancer on a molecular…

Articles about Sividon Diagnostics' Acquisition: